Covered Wagon Max 56% OFF Wagon,$12,Covered,Movies TV , Blu-ray , Movies,capshine.co.uk,/menses188222.html Covered Wagon Max 56% OFF Wagon,$12,Covered,Movies TV , Blu-ray , Movies,capshine.co.uk,/menses188222.html $12 Covered Wagon Movies TV Blu-ray Movies $12 Covered Wagon Movies TV Blu-ray Movies

Covered Max 74% OFF Wagon Max 56% OFF

Covered Wagon

$12

Covered Wagon

|||

Editorial Reviews

The first Western epic! A great caravan of covered wagons, filled with hearty pioneers and their families and possessions, are waiting for the Spring jump off at Westport Landing, now Kansas City. The time is 1848, and the destination is far-off Oregon, in The Covered Wagon (1923), the first big-budget Western epic. Where countless pilgrims fell, a love triangle flourishes, as Molly Wingate (Lois Wilson) must choose between the brutish Sam (Alan Hale) and the dashing Will (J. Warren Kerrigan). Complicating her decision are the perils of the trail: a mile-wide river, prairie fire, heavy snowfall, a buffalo stampede, crippling hunger, and Native American attacks. Boasting a cast of thousands and an unparalleled commitment to authenticity, The Covered Wagon was an enormous box-office success in 1923 and became one of the major milestones in the history of the Western.

Special Features:
-Audio commentary by Film Historian Toby Roan
-Booklet essay by film scholar Matt Hauske
-The Pie-Covered Wagon: a 1932 one-reel spoof starring Shirley Temple
-Wurlitzer organ score by Gaylord Carter
-Reversible Blu-ray Art

Covered Wagon

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA